Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4) 4
ophthalmology (4) 4
abridged index medicus (2) 2
adiabatic (2) 2
aged (2) 2
analog (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal - adverse effects (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - adverse effects (2) 2
association (2) 2
autism (2) 2
bevacizumab (2) 2
biomedical (2) 2
brain-machine interface (2) 2
compression (2) 2
dose-response relationship, drug (2) 2
eye disease (2) 2
female (2) 2
hepatocellular carcinoma (2) 2
humans (2) 2
implantable electronics (2) 2
liver (2) 2
low power (2) 2
male (2) 2
meeting abstracts (2) 2
nivolumab (2) 2
patients (2) 2
ranibizumab (2) 2
research (2) 2
risk (2) 2
safety (2) 2
safety engineering (2) 2
solid tumors (2) 2
spectrum disorder (2) 2
stimulation (2) 2
therapy (2) 2
tumors (2) 2
12-month outcomes (1) 1
4-1bb (1) 1
4-1bb ligand (1) 1
4-1bb ligand - agonists (1) 1
abnormalities (1) 1
acceptability (1) 1
activation (1) 1
adult (1) 1
adults (1) 1
aflibercept (1) 1
american-college (1) 1
antibodies, monoclonal (1) 1
antibodies, monoclonal - pharmacokinetics (1) 1
antineoplastic agents (1) 1
antineoplastic agents - pharmacokinetics (1) 1
apolipoprotein-e (1) 1
apoptosis (1) 1
arms2 (1) 1
autism spectrum disorders (1) 1
b7 antigen (1) 1
b7-h1 antigen - metabolism (1) 1
behavioural genetics (1) 1
best practices (1) 1
biochemical research methods (1) 1
biogeochemistry (1) 1
biomarkers, tumor - metabolism (1) 1
blockade (1) 1
cancer (1) 1
cancer therapies (1) 1
cancer-immunotherapy (1) 1
capacitance (1) 1
capacitors (1) 1
carcinoma, hepatocellular - drug therapy (1) 1
carcinoma, hepatocellular - pathology (1) 1
care and treatment (1) 1
cd137 (1) 1
cd137 antigen (1) 1
cell death (1) 1
cell lung-cancer (1) 1
classification (1) 1
clinical trial, phase i (1) 1
clinical trial, phase ii (1) 1
clinical trials (1) 1
coastal (1) 1
college teachers (1) 1
comparative analysis (1) 1
complement (1) 1
congenital diseases (1) 1
consortia (1) 1
copy-number variation (1) 1
cytokines (1) 1
data processing (1) 1
data sharing (1) 1
de-novo mutations (1) 1
deep (1) 1
definition (1) 1
degeneration (1) 1
discovery (1) 1
disease (1) 1
docetaxel (1) 1
dosage (1) 1
drug administration schedule (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
by El-Khoueiry, Anthony B, Dr and Sangro, Bruno, MD and Yau, Thomas, MD and Crocenzi, Todd S, MD and Kudo, Masatoshi, MD and Hsu, Chiun, MD and Kim, Tae-You, MD and Choo, Su-Pin, BMBS and Trojan, Jörg, MD and Welling, Theodore H, MD and Meyer, Tim, MD and Kang, Yoon-Koo, MD and Yeo, Winnie, MD and Chopra, Akhil, MD and Anderson, Jeffrey, MD and dela Cruz, Christine, MD and Lang, Lixin, PhD and Neely, Jaclyn, PhD and Tang, Hao, PhD and Dastani, Homa B, PhD and Melero, Ignacio
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10088, pp. 2492 - 2502
Summary Background For patients with advanced hepatocellular carcinoma, sorafenib is the only approved drug worldwide, and outcomes remain poor. We aimed to... 
Internal Medicine | CELL LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | IMMUNOTHERAPY | SORAFENIB | BLOCKADE | DOCETAXEL | PD-1 | Drug Administration Schedule | Humans | Antibodies, Monoclonal - adverse effects | Liver Neoplasms - drug therapy | Male | Response Evaluation Criteria in Solid Tumors | Treatment Outcome | Antineoplastic Agents - administration & dosage | Tumor Burden | Dose-Response Relationship, Drug | B7-H1 Antigen - metabolism | Carcinoma, Hepatocellular - drug therapy | Time Factors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Nivolumab | Carcinoma, Hepatocellular - pathology | Biomarkers, Tumor - metabolism | Female | Liver Neoplasms - pathology | Aged | Virus diseases | Medical colleges | Care and treatment | Cell death | College teachers | Hepatoma | Comparative analysis | Drug approval | Slopes | Therapy | Pemphigoid | Intravenous administration | Inhibitor drugs | PD-1 protein | Funding | Liver | Medical services | Clinical trials | Hepatocellular carcinoma | Lymphocytes T | Infections | Metastasis | Dosage | Cancer therapies | B7 antigen | Acceptability | Incidence | Hepatitis | Liver cancer | Pathways | Quality | Immunotherapy | Safety engineering | Safety management | Safety | Expansion | Drug dosages | Liver diseases | Effectiveness | Mortality | Group dynamics | Patients | Hospitals | Inhibitors | Immune checkpoint | Adults | Solid tumors | Hepatitis C virus | Hepatitis C | Tumors | Apoptosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody
by Segal, Neil H and Logan, Theodore F and Hodi, F. Stephen and McDermott, David and Melero, Ignacio and Hamid, Omid and Schmidt, Henrik and Robert, Caroline and Chiarion-Sileni, Vanna and Ascierto, Paolo A and Maio, Michele and Urba, Walter J and Gangadhar, Tara C and Suryawanshi, Satyendra and Neely, Jaclyn and Jure-Kunkel, Maria and Krishnan, Suba and Kohrt, Holbrook and Sznol, Mario and Levy, Ronald
Clinical Cancer Research, ISSN 1078-0432, 04/2017, Volume 23, Issue 8, pp. 1929 - 1936
Purpose: Urelumab is an agonist antibody to CD137 with potential application as an immuno-oncology therapeutic. Data were analyzed to assess safety,... 
ACTIVATION | THERAPY | MELANOMA | ONCOLOGY | 4-1BB | MICE | CANCER-IMMUNOTHERAPY | CD137 | TUMORS | IPILIMUMAB | 4-1BB Ligand - agonists | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - pharmacokinetics | Male | Antineoplastic Agents - administration & dosage | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Melanoma - drug therapy | Adult | Female | Aged | Antineoplastic Agents - pharmacokinetics | Evaluation | CD137 antigen | Cytokines | Liver | Abnormalities | Fatigue | Data processing | Nausea | Pharmacology | Patients | Lymphoma | Experimental design | Safety engineering | Monoclonal antibodies | Interferon | Safety | Solid tumors | Tumors | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text A 4.78 mm2 Fully-Integrated Neuromodulation SoC Combining 64 Acquisition Channels with Digital Compression and Simultaneous Dual Stimulation
by Biederman, William and Yeager, Daniel J and Narevsky, Nathan and Leverett, Jaclyn and Neely, Ryan and Carmena, Jose M and Alon, Elad and Rabaey, Jan M
IEEE Journal of Solid-State Circuits, ISSN 0018-9200, 04/2015, Volume 50, Issue 4, pp. 1038 - 1047
analog | Adiabatic | implantable electronics | low power | compression | biomedical | brain-machine interface | stimulation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text SPARK: A US Cohort of 50,000 Families to Accelerate Autism Research
by Feliciano, Pamela and Daniels, Amy M and Green Snyder, LeeAnne and Beaumont, Amy and Camba, Alexies and Esler, Amy and Gulsrud, Amanda G and Mason, Andrew and Gutierrez, Anibal and Nicholson, Amy and Paolicelli, Anna Marie and McKenzie, Alexander P and Rachubinski, Angela L and Stephens, Alexandra N and Simon, Laura and Simon, Andrea R and Stedman, Amy and Shocklee, Amanda D and Swanson, Amy and Finucane, Brenda and Hilscher, Brittani A and Hauf, Brenda and O’Roak, Brian J and McKenna, Brooke and Robertson, Beverly E and Rodriguez, Barbara and Vernoia, Brianna M and Van Metre, Bonnie and Bradley, Catherine and Cohen, Cheryl and Erickson, Craig A and Harkins, Christina and Hayes, Caitlin and Lord, Catherine and Martin, Christa Lese and Ortiz, Crissy and Ochoa-Lubinoff, Cesar and Peura, Christine and Rice, Catherine E and Rosenberg, Cordelia R and Smith, Christopher J and Smith, Kaitlin and Thomas, Carrie and Taylor, Cora M and White, Loran Casey and White, Sabrina and Walston, Corrie H and Amaral, David G and Coury, Daniel Lee and Sarver, Dustin E and Istephanous, Dalia and Li, Deana and Li, Hai and Nugyen, Dzung Cong and Fox, Emily A and Butter, Eric M and Berry-Kravis, Elizabeth and Courchesne, Eric and Fombonne, Eric J and Hofammann, Eugenia and Lamarche, Elena and Wodka, Ericka L and Matthews, Emily T and O’Connor, Eirene and Palen, Emily and Miller, Fiona and Dichter, Gabriel S and Marzano, Gabriela and Stein, Gail and Hutter, Hanna and Kaplan, Hannah E and Lechniak, Holly and Schneider, Hoa Lam and Zaydens, Hana and Arriaga, Ivette and Gerdts, Jennifer A and Cubells, Joseph F and Cordova, Jeanette M and Gunderson, Jaclyn and Lillard, Joseph and Manoharan, Julie and McCracken, James T and Michaelson, Jacob J and Neely, Jason and Orobio, Jessica and Pandey, Juhi and Piven, Joseph and Scherr, Jessica and Sutcliffe, James S and Tjernagel, Jennifer and Wallace, Jermel and Callahan, Kristen and Dent, Katherine and Schweers, Kathryn A and Hamer, Kira E and Law, J. Kiely and Lowe, Kathryn and O’Brien, Kaela and Pawlowski, Katherine G and Pierce, Karen L and ... and SPARK Consortium and SPARK Consortium. Electronic address: pfeliciano@simonsfoundation.org
Neuron, ISSN 0896-6273, 02/2018, Volume 97, Issue 3, pp. 488 - 493
The Simons Foundation Autism Research Initiative (SFARI) has launched , a dynamic platform that is engaging thousands of individuals with autism spectrum... 
RISK | NEUROSCIENCES | SPECTRUM DISORDER | DISEASE | Autism | Family | Congenital diseases | Working groups | Genomics | Genes | Families & family life | Systematic review | Genomes | Research | Environmental risk | Meta-analysis | Studies | Consortia | Researchers | Mutation | Pollutants
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text MO2-11-1 [Encore]Biomarkers and clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma in CheckMate 040
by Melero, Ignacio and Neely, Jaclyn and Sangro, Bruno and Finn, Richard S and Abou-Alfa, Ghassan K and Cheng, Ann-Lii and Yau, Thomas and Furuse, Junji and Park, Joong-Won and Wadhawan, Samir and Tang, Hao and Anderson, Jeffrey and Boyd, Zachary and El-Khoueiry, Anthony
Annals of Oncology, ISSN 0923-7534, 10/2019, Volume 30, Issue Supplement_6
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Tu1483 - Hepatic Safety and Biomarker Assessments in Sorafenibexperienced Patients with Advanced Hepatocellular Carcinoma Treated with Nivolumab in the Checkmate-040 Study
by Crocenzi, Todd and Meyer, Tim and Melero, Ignacio and Yau, Thomas and Hsu, Chiun and Kudo, Masatoshi and Choo, Su-Pin and Trojan, Jorg and Welling, Theodore and Kang, Yoon-Koo and Yeo, Winnie and Chopra, Akhil and Baakili, Adyb and Cruz, Christine dela and Zhao, Huanyu and Neely, Jaclyn and El-Khoueiry, Anthony and Sangro, Bruno
Gastroenterology, ISSN 0016-5085, 05/2018, Volume 154, Issue 6, pp. S-1234 - S-1234
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459
by Sangro, Bruno and Park, Joong-Won and Dela Cruz, Christine Marie and Anderson, Jeffrey and Lang, Lixin and Neely, Jaclyn and Shaw, James W and Cheng, Ann-Lii
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. TPS4147 - TPS4147
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A 4.78 mm 2 Fully-Integrated Neuromodulation SoC Combining 64 Acquisition Channels With Digital Compression and Simultaneous Dual Stimulation
by Biederman, William and Yeager, Daniel J and Narevsky, Nathan and Leverett, Jaclyn and Neely, Ryan and Carmena, Jose M and Alon, Elad and Rabaey, Jan M
IEEE Journal of Solid-State Circuits, ISSN 0018-9200, 04/2015, Volume 50, Issue 4, pp. 1038 - 1047
A 65 nm CMOS 4.78 mm 2 integrated neuromodulation SoC consumes 348 μA from an unregulated 1.2 V to 1.8 V supply while operating 64 acquisition channels with... 
Power demand | Noise | Capacitors | Adiabatic | biomedical | Electrodes | analog | Capacitance | implantable electronics | low power | System-on-chip | compression | Gain | brain-machine interface | stimulation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040
by Yau, Thomas and Kang, Yoon-Koo and Kim, Tae-You and El-Khoueiry, Anthony B and Santoro, Armando and Sangro, Bruno and Melero, Ignacio and Kudo, Masatoshi and Hou, Ming-Mo and Matilla, Ana and Tovoli, Francesco and Knox, Jennifer J and He, Aiwu Ruth and El-Rayes, Bassel F and Acosta-Rivera, Mirelis and Neely, Jaclyn and Shen, Yun and Baccan, Carlos and Dela Cruz, Christine Marie and Hsu, Chiun
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 4012 - 4012
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text FRI-499-Efficacy and hepatic safety of nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040
by Sangro, Bruno and Matilla, Ana M and Santoro, Armando and Melero, Ignacio and Gracian, Antonio Cubillo and Acosta, Mirelis Rivera and Choo, Su-Pin and El-Khoureiry, Anthony and Kuromatsu, Ryoko and El-Rayes, Bassel and Numata, Kazushi and Itoh, Yoshito and Costanzo, Francesco Di and Crysler, Oxana and Reig, MarĂ­a and Shen, Yun and Neely, Jaclyn and Cruz, Christine Dela and Baccan, Carlos and Kudo, Masatoshi
Journal of Hepatology, ISSN 0168-8278, 04/2019, Volume 70, Issue 1, pp. e619 - e619
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status
by Kudo, Masatoshi and Matilla, Ana and Santoro, Armando and Melero, Ignacio and Gracian, Antonio Cubillo and Acosta-Rivera, Mirelis and Choo, Su Pin and El-Khoueiry, Anthony B and Kuromatsu, Ryoko and El-Rayes, Bassel F and Numata, Kazushi and Itoh, Yoshito and Di Costanzo, Francesco and Crysler, Oxana V and Reig, Maria and Shen, Yun and Neely, Jaclyn and Dela Cruz, Christine Marie and Baccan, Carlos and Sangro, Bruno
Journal of Clinical Oncology, ISSN 0732-183X, 02/2019, Volume 37, Issue 4_suppl, pp. 327 - 327
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study
by Sangro, Bruno and Melero, Ignacio and Yau, Thomas Cheung and Hsu, Chiun and Kudo, Masatoshi and Crocenzi, Todd S and Kim, Tae-You and Choo, SuPin and Trojan, Jorg and Meyer, Tim and Kang, Yoon-Koo and Anderson, Jeffrey and Dela Cruz, Christine Marie and Lang, Lixin and Neely, Jaclyn and El-Khoueiry, Anthony B
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. 4078 - 4078
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Phase I/II safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of the CheckMate-040 dose escalation study
by El-Khoueiry, Anthony B and Sangro, Bruno and Yau, Thomas Cheung and Crocenzi, Todd S and Welling, Theodore Hobart and Yeo, Winnie and Chopra, Akhil and Anderson, Jeffrey and Dela Cruz, Christine Marie and Lang, Lixin and Neely, Jaclyn and Melero, Ignacio
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. 4012 - 4012
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study
by Crocenzi, Todd S and El-Khoueiry, Anthony B and Yau, Thomas Cheung and Melero, Ignacio and Sangro, Bruno and Kudo, Masatoshi and Hsu, Chiun and Trojan, Jorg and Kim, Tae-You and Choo, Su-Pin and Meyer, Tim and Kang, Yoon-Koo and Yeo, Winnie and Chopra, Akhil and Baakili, Adyb and Dela Cruz, Christine Marie and Lang, Lixin and Neely, Jaclyn and Welling, Theodore
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. 4013 - 4013
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study
by Melero, Ignacio and Sangro, Bruno and Yau, Thomas Cheung and Hsu, Chiun and Kudo, Masatoshi and Crocenzi, Todd S and Kim, Tae-You and Choo, SuPin and Trojan, Jorg and Meyer, Tim and Welling, Theodore Hobart and Yeo, Winnie and Chopra, Akhil and Anderson, Jeffrey and Dela Cruz, Christine Marie and Lang, Lixin and Neely, Jaclyn and Tang, Hao and El-Khoueiry, Anthony
Journal of Clinical Oncology, ISSN 0732-183X, 02/2017, Volume 35, Issue 4_suppl, pp. 226 - 226
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Progress and Challenges in Ocean Metaproteomics and Proposed Best Practices for Data Sharing
by Saito, Mak A and Bertrand, Erin M and Duffy, Megan E and Gaylord, David A and Held, Noelle A and Hervey, William Judson and Hettich, Robert L and Jagtap, Pratik D and Janech, Michael G and Kinkade, Danie B and Leary, Dagmar H and McIlvin, Matthew R and Moore, Eli K and Morris, Robert M and Neely, Benjamin A and Nunn, Brook L and Saunders, Jaclyn K and Shepherd, Adam I and Symmonds, Nicholas I and Walsh, David A and Oak Ridge National Lab. (ORNL), Oak Ridge, TN (United States)
Journal of Proteome Research, ISSN 1535-3893, 2019, Volume 18, Issue 4, pp. 1461 - 1476
Ocean metaproteomics is an emerging field enabling discoveries about marine microbial communities and their impact on global biogeochemical processes. Recent... 
Metaproteomics | ocean | biogeochemistry | data sharing | best practices | SHOTGUN PROTEOMICS | BIOCHEMICAL RESEARCH METHODS | PROTEIN INFERENCE | COASTAL | IRON | IDENTIFICATION | SEA | DISCOVERY | PEPTIDES | DEEP | MICROBIAL COMMUNITIES | ENVIRONMENTAL SCIENCES
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16
by Keenan, Tiarnan D and AgrĂ³n, Elvira and Domalpally, Amitha and Clemons, Traci E and van Asten, Freekje and Wong, Wai T and Danis, Ronald G and Sadda, SriniVas and Rosenfeld, Philip J and Klein, Michael L and Ratnapriya, Rinki and Swaroop, Anand and Ferris, Frederick L and Chew, Emily Y and Chew, Emily Y and Ferris, Frederick L and SanGiovanni, John Paul and AgrĂ³n, Elvira and Clemons, Traci and Lindblad, Anne and Lindblad, Robert and Shah, Nilay and Sperduto, Robert and McBee, Wendy and Gensler, Gary and Harrington, Molly and Henning, Alice and Jones, Katrina and Thotapally, Kumar and Tull, Diana and Watson, Valerie and Williams, Kayla and Gentry, Christina and Kaufman, Francine and Morrison, Chris and Saverino, Elizabeth and Schenning, Sherrie and Blodi, Barbara and Danis, Ronald P and Davis, Matthew and Domalpally, Amitha and Glander, Kathy and Guilfoil, Gregory and Hubbard, Larry D and Johnson, Kristine and Klein, Ronald and Nardi, Barbara and Neider, Michael and Robinson, Nancy and Rosensteel, Eileen and Wabers, Hugh and Zhang, Grace and Ruby, Alan J and Capone, Antonio and Dass, Bawa and Drenser, Kimberly and Garretson, Bruce R and Hassan, Tarek S and Trese, Michael and Williams, George A and Wolfe, Jeremy and Bell, Tina and Zajechowski, Mary and Bezaire, Dennis and McIver, Fran and Medina, Anthony and Pagett, Jackie and Smith, Stephanie Hatch and Swartz, Lynn and Treuter, Tom and Antoszyk, Andrew and Brown, Justin and Browning, David J and Holland, Walter and Karow, Angella and Stalford, Kelly and Price, Angela and Ennis, Sarah and Fredenberg, Sherry and Herby, Jenna and Balasubramaniam, Uma and Clark, Loraine and McClain, Donna and McOwen, Michael and Watson, Lynn and Klein, Michael and Bailey, Steven T and Hwang, Thomas J and Lauer, Andreas and Stout, J. Timothy and McCollum, Patty and Johnson, Milt and Rice, Patrick B and Kim, Ivana and Loewenstein, John and Miller, Joan and Sobrin, Lucia and Young, Lucy and Sullivan, Jacqueline and Houlihan, Patricia and ... and AREDS2 Res Grp and AREDS2 Research Group
Ophthalmology, ISSN 0161-6420, 12/2018, Volume 125, Issue 12, pp. 1913 - 1928
Purpose: To analyze the prevalence, incidence, and clinical characteristics of eyes with geographic atrophy (GA) in age-related macular degeneration (AMD),... 
PHOTOGRAPHS | DEFINITION | EYE DISEASE | COMPLEMENT | INFLAMMATION | GROWTH | FUNDUS AUTOFLUORESCENCE IMAGES | OPHTHALMOLOGY | END-POINTS | ASSOCIATION | APOLIPOPROTEIN-E
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti–Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema
by Jampol, Lee M and Glassman, Adam R and Liu, Danni and Liu, Judy C and Aiello, Lloyd Paul and Aiello, Lloyd P and Bressler, Neil M and Bressler, Susan B and Duh, Elia J and Quaggin, Susan and Wells, Michael B and Wells, John A and Wykoff, Charles C and Browning, David and Antoszyk, Andrew N and Antoszyk, Andrew and Price, Randall L and Price, Angela K and Price, Paula A and Fredenberg, Sherry L and Herby, Jenna T and Fleming, Christina J and McClain, Ashley A and McClain, Ashley and McClain, Donna and Ennis, Sarah A and Gallagher, Kelly R and Karow, Angella S and Grupp, Autumn C and Puskas, Danielle and Watson, Brandun and Watson, Lynn and Bojaj, Swann J and Balasubramaniam, Uma M and Styles, Donna R and Kuopus, Jeff A and Kimrey, Kathryn and Clark, Mark D and Clark, Loraine M and Clark, W. Lloyd and Jackson, Lisa A and McOwen, Michael D and Dunlap, Matt and Held, Susannah J and Pieramici, Dante J and Nasir, Ma'an A and Castellarin, Alessandro A and Dhoot, Dilsher and Fishbein, Sarah and Giust, Jack and Giust, Matthew and Wan, Lisha and Hanna, Michelle S and Rabena, Melvin D and Smith, Veronica A and Smith, Jerry and Smith, Christopher M and Smith, Bradley T and Bone, Layne J and Avery, Kelly and Walker, Aimee and Walker, Joseph P and Walker, Cathy and Shook, Aimee H and Esau, Sara and Ruvalcaba, Nitce L and Johnson, Tametha and Johnson, Melissa L and Johnson, David L and Johnson, Marilyn A and Johnson, Britta and Johnson, Paula A and Payne, John F and Swinford, Tiffany R and Taylor, Mallie M and Taylor, Gena and Taylor, Teresa and Garrison, Cassandra L and Miller, Heather R and Miller, Pam S and Miller, Peggy D and Miller, David T and Miller, David G and Houlahan, Amber R and O'Neill, Charlotte A and Floyd, Geri L and Floyd, Ashley and Parker, Marianne and Parker, Crystal C and Sease, Courtney and Graham, Margie and Graham, Tara and Spencer, Robin and Ogbuewu, Tiffany N and Studebaker, Ashley and Huggins, Meagan L and Huggins, Tyler and Spivey, Robbin and Jones, Brian and Jones, Michael Cullen and ... and Diabet Retinopathy Clinical Res Ne and Diabetic Retinopathy Clinical Research Network
Ophthalmology, ISSN 0161-6420, 07/2018, Volume 125, Issue 7, pp. 1054 - 1063
To assess systemic vascular endothelial growth factor (VEGF)-A levels after treatment with intravitreous aflibercept, bevacizumab, or ranibizumab.... 
METAANALYSIS | PHARMACOKINETICS | BEVACIZUMAB | INJECTION | OPHTHALMOLOGY | RETINOPATHY | SERUM | RANIBIZUMAB | PREMATURITY | DEGENERATION
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights